JW Pharmaceutical KRX:001060KOSPI
JW중외제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h2
Articles, 7 days4
DART filings, 7 days0
Articles tracked4since Sep 11
In Q2 2026, JW Pharmaceutical reported revenue of ₩222bn, up 16.2% year on year, and operating profit of ₩33.3bn. JW Pharmaceutical (JW중외제약) appeared in 4 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 14 with 3 articles. The most common catalyst was clinical & approvals (1). It was most often mentioned alongside DongKookPharmaceutical.
JW Pharmaceutical quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩222bn | +16.2% | ₩33.3bn | ₩27.9bn |
| Q1 2026 | ₩200bn | +7.9% | ₩33.6bn | ₩27.5bn |
| Q4 2025 derived | ₩199bn | +5.9% | ₩15.5bn | ₩15.3bn |
| Q3 2025 | ₩200bn | +12.0% | ₩32.0bn | ₩30.6bn |
| Q2 2025 | ₩191bn | +10.9% | ₩25.0bn | −₩1.9bn |
| Q1 2025 | ₩185bn | +2.6% | ₩22.0bn | ₩17.5bn |
| Q4 2024 derived | ₩188bn | -8.4% | ₩18.1bn | ₩16.6bn |
| Q3 2024 | ₩179bn | -3.0% | ₩26.5bn | ₩19.8bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
JW Pharmaceutical top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
